Navigation Links
Lilly Sets Date for 2013 Diabetes Pipeline Update to the Media and Investment Community
Date:3/5/2013

INDIANAPOLIS, March 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call for the media and investment community to provide a pipeline update for its diabetes business on Monday, June 24, 2013. The call, which is being held in conjunction with the 73rd American Diabetes Association Scientific Sessions, will include updates on Phase III data for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor, and dulaglutide, an investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist. Empagliflozin is in development in partnership with Boehringer Ingelheim.  

The conference call will be held from 7 p.m. to 8:30 p.m. US Central Time (CDT). Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at www.lilly.com. The webcast of the conference call will be available for replay through July 24, 2013.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions—from medicines to support programs and more—to make lives better. For more information, visit www.lillydiabetes.com.

P-LLY

Refer to:

(317) 701-4007 – Kelley Murphy (media)


(317) 655-6874 – Philip Johnson (investors)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
(Logo: http://photos.prnewswire.com/prnh/20111111/DE03493LOGO


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
2. Lillys Team Solutions and Solutions for Wellness Resources for Serious Mental Illness Added to SAMHSAs Distinguished National Registry
3. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
4. Lilly Diabetes celebrates six years of scholarship support for American Diabetes Association diabetes summer camps by sending 90 children to camp in 2013
5. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
6. Lilly Recognized for Fifth Straight Year on NAFEs Top 50 Companies for Executive Women
7. Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance
8. NYSE Hot Stocks Earnings Forecast: Wells Fargo, Eli Lilly, Berkshire Hathaway, Coca-Cola, Valero Energy, and Altria Group
9. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
10. Lilly Provides Update on Next Steps for Solanezumab
11. Lilly to Expand Indianapolis Insulin Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading ... by Accera, Inc. at 11 a.m. EST ... International Conference on Clinical Trials for Alzheimer,s Disease (CTAD). ... metabolism in Alzheimer,s disease and therapeutic targets that address ... "Following the recent failure of another therapy targeting ...
(Date:12/5/2016)... Dec 5, 2016 Research and Markets ... Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End ... Forecasts to 2021" report to their offering. ... , , ... Million in 2021 from USD 574.8 Million in 2016, growing at ...
(Date:12/5/2016)... December 5, 2016 According to a new report published ... Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the global ... reach $5,255 million by 2022, growing at a CAGR of 6.4% from 2016 ... four-fifths share. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... The new ... the individual looking to buy neoprene knee sleeves for lifting and any ... design focuses heavily on two main aspects to provide a higher quality knee sleeve ...
(Date:12/5/2016)... Wallingford, CT (PRWEB) , ... December 05, 2016 ... ... hemostatic devices, announces today that they have teamed up with The American College ... Working with the ACS’s Committee on Trauma, the “Bleeding Control Basic” course is ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... transitions and many more tools allowing FCPX editors to create professional looking video ... Studios. , Perfect Harmony contains a beautifully designed 3D environment for placing ...
(Date:12/4/2016)... Viejo, California (PRWEB) , ... December 04, 2016 ... ... lower third presets that have new attractive animation styles with unique displacement design ... Displace features 30 pre-animated lower third designs. Choose from a variety of design ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
Breaking Medicine News(10 mins):